Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.
[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)]
7992332
{7992332:CCCCCCCC}
apa
50
1
169058
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
